Last reviewed 2026-04-23 · How we verify

CNTO 1275

CNTO 1275 is a fully human monoclonal antibody that targets the CD28 receptor.

CNTO 1275 is a fully human monoclonal antibody that targets the CD28 receptor. Used for Rheumatoid arthritis.

At a glance

Mechanism of action

By binding to CD28, CNTO 1275 modulates T-cell activation and proliferation, which may help to prevent or treat autoimmune diseases.

Approved indications

• Rheumatoid arthritis

Common side effects

• Headache
• Fatigue
• Nausea

Key clinical trials

• Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt
• A Prospective Observational Study on the Efficacy and Safety of Guselkumab in the Treatment of Crohn's Disease Patients Previously Treated With Ustekinumab
• A Long-term Extension Study of Ustekinumab in Pediatric Participants (PHASE3)
• A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease (PHASE4)
• Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)
• A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD) (PHASE4)
• A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (PHASE2, PHASE3)
• A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.